In 2023, Nanjing Damei Biopharmaceutical developed ATR inhibitors particularly effective against cancers with impaired DNA repair mechanisms, including those with BRCA1/2 mutations, PTEN loss, or ATM deficiency. This evidence concerns the gene BRCA1 and cancer.